

Press Coverage | March 28, 2022

Biotech Startup Fundraising Has Been Resilient, But Investors Are Selective

RELATED PROFESSIONALS

[Christopher S. Miller](#)

Chris Miller, a partner with Troutman Pepper, is quoted in the *WSJ Pro Venture Capital* article, "[Biotech Startup Fundraising Has Been Resilient, But Investors Are Selective.](#)"

When biotech stocks were soaring early last year, startups and venture investors rushed to complete financings, said Chris Miller, a partner with law firm Troutman Pepper Hamilton Sanders LLP.

Now, deals are taking longer and investors often mete out rounds in tranches, dispersing some funding up front and the rest as the company meets certain goals, he said. Such measures weren't the norm last year, he added.

RELATED INDUSTRIES + PRACTICES

- [Corporate](#)
- [Emerging Companies + Venture Capital](#)